

AstraZeneca



December 24, 2009

Canadian Intellectual Property Office  
Patent Branch  
50 Victoria Street,  
Place du Portage II  
Gatineau, QC K1A 0C9

Dear Mr. Evans,

**RE: Consultation regarding MOPOP Chapter 9: Description**

AstraZeneca Canada Inc. (AstraZeneca) would like to take the opportunity to provide brief comments on the draft revised Chapter 9: Description of the Manual of Patent Office Practice (MOPOP). We appreciate the Patent Office's willingness to consider stakeholder comments.

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and a supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US\$ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. Intellectual property rights are very important to our business.

We have reviewed the submissions of the association of Canada's Research-Based Pharmaceutical Companies (Rx&D). We agree with and support those submissions.

If you have any questions or comments, please do not hesitate to contact me by telephone at (905) 896-6120, or by fax at (905) 277-5627.

Sincerely,

ASTRAZENECA CANADA INC.

Denise Lacombe  
Legal Counsel